A299660 Stock Overview
Develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cellid, Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,590.00 |
| 52 Week High | ₩17,310.00 |
| 52 Week Low | ₩1,733.00 |
| Beta | 1.49 |
| 11 Month Change | 189.23% |
| 3 Month Change | 138.61% |
| 1 Year Change | 45.84% |
| 33 Year Change | -93.27% |
| 5 Year Change | -58.80% |
| Change since IPO | -83.19% |
Recent News & Updates
Shareholder Returns
| A299660 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -39.6% | 1.7% | 1.9% |
| 1Y | 45.8% | 36.3% | 3.6% |
Return vs Industry: A299660 exceeded the KR Biotechs industry which returned 36.3% over the past year.
Return vs Market: A299660 exceeded the KR Market which returned 3.6% over the past year.
Price Volatility
| A299660 volatility | |
|---|---|
| A299660 Average Weekly Movement | 27.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A299660's share price has been volatile over the past 3 months.
Volatility Over Time: A299660's weekly volatility has increased from 16% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Yuil Kang Chang | www.cellid.co.kr |
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo, a customized immunotherapeutic vaccine; and COVID-19 prevention vaccines.
Cellid, Co., Ltd. Fundamentals Summary
| A299660 fundamental statistics | |
|---|---|
| Market cap | ₩181.27b |
| Earnings (TTM) | -₩10.36b |
| Revenue (TTM) | ₩914.19m |
198.3x
P/S Ratio-17.5x
P/E RatioIs A299660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A299660 income statement (TTM) | |
|---|---|
| Revenue | ₩914.19m |
| Cost of Revenue | ₩908.19m |
| Gross Profit | ₩6.00m |
| Other Expenses | ₩10.37b |
| Earnings | -₩10.36b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -491.05 |
| Gross Margin | 0.66% |
| Net Profit Margin | -1,133.52% |
| Debt/Equity Ratio | 27.7% |
How did A299660 perform over the long term?
See historical performance and comparison